After a fourth quarter in which revenue boomed throughout the biopharma industry, there were reversals for several drugmakers ...

US President Donald Trump’s tariff hammer against the European Union caused stock markets to falter at the close of the ...

Bayer announces EMA committee recommends label extension approval for Eylea 8 mg: Berlin Monday, May 26, 2025, 17:00 Hrs [IST] Bayer announced that the Committee for Medicinal Pro ...

This update covers the latest health sector developments, including Moderna's COVID-19 vaccine review, GSK's asthma drug FDA ...

Eylea, developed by Regeneron, is the world’s leading treatment for age-related macular degeneration, a common cause of blindness in older adults. Since its launch in 2013, Eylea has become a major ...

German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of ...

BAYRY's Eylea 8 mg gets CHMP nod in EU, promising 6-month dosing for nAMD and DME with strong 3-year efficacy and safety data ...

Bayer A.G. ( OTCPK:BAYZF) ( OTCPK:BAYRY) said that an advisory panel of the European Medicines Agency (EMA), endorsed the ...

An EMA committee has issued a positive opinion for a label extension that would allow six-month injection intervals for Eylea ...

Characteristics of the included trials on non-pharmacological treatment. ASDAS, Ankylosing Spondylitis Disease Activity Score; ASQoL, Ankylosing Spondylitis Quality of Life; BASDAI, Bath Ankylosing ...

China’s NMPA approves Eylea 8 mg for wet age-related macular degeneration: Berlin Friday, May 23, 2025, 09:00 Hrs [IST] The Center for Drug Evaluation (CDE) of China’s Nationa ...